These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 11929798)

  • 1. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.
    Hartwig UF; Robbers M; Wickenhauser C; Huber C
    Blood; 2002 Apr; 99(8):3041-9. PubMed ID: 11929798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of Alloreactive T-Cells by Anti-CD137-Saporin Immunotoxin.
    Lee SC; Seo KW; Kim HJ; Kang SW; Choi HJ; Kim A; Kwon BS; Cho HR; Kwon B
    Cell Transplant; 2015; 24(6):1167-81. PubMed ID: 24594433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process.
    Chen BJ; Cui X; Liu C; Chao NJ
    Blood; 2002 May; 99(9):3083-8. PubMed ID: 11964269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated allogeneic NK cells as suppressors of alloreactive responses.
    Hu B; He Y; Wu Y; Bao G; Liu H; Welniak LA; Murphy WJ
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):772-81. PubMed ID: 20197103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69).
    Fehse B; Frerk O; Goldmann M; Bulduk M; Zander AR
    Br J Haematol; 2000 Jun; 109(3):644-51. PubMed ID: 10886218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of alloreactive donor T cells using immunomagnetic cell selection.
    Fehse B; Goldmann M; Frerk O; Bulduk M; Zander AR
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S39-42. PubMed ID: 10933186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.
    Wehler TC; Nonn M; Brandt B; Britten CM; Gröne M; Todorova M; Link I; Khan SA; Meyer RG; Huber C; Hartwig UF; Herr W
    Blood; 2007 Jan; 109(1):365-73. PubMed ID: 16931626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting T Cell Bioenergetics by Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells To Prevent Graft-versus-Host Disease.
    McIver ZA; Grayson JM; Coe BN; Hill JE; Schamerhorn GA; Ohulchanskyy TY; Linder MK; Davies KS; Weiner RS; Detty MR
    J Immunol; 2016 Sep; 197(5):1631-41. PubMed ID: 27456485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
    Hartwig UF; Nonn M; Khan S; Link I; Huber C; Herr W
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):99-109. PubMed ID: 18158966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
    Fujioka T; Taniguchi Y; Masuda T; Nishida S; Ikegame K; Kawakami M; Tsuboi A; Hosen N; Murakami M; Oji Y; Oka Y; Sugiyama H; Kawase I; Ogawa H
    Transpl Immunol; 2003; 11(2):187-95. PubMed ID: 12799203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation.
    Godfrey WR; Krampf MR; Taylor PA; Blazar BR
    Blood; 2004 Feb; 103(3):1158-65. PubMed ID: 14525783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
    Georgantas RW; Bohana-Kashtan O; Civin CI
    Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of rotor off fraction in allogeneic murine bone marrow transplantation with complete disparity of major histocompatibility.
    Jeong DC; Han CW; Jin JY; Kim DS; Choi IB; Kim WI; Kim HK; Kim CC; Lee BC; Imamura M; Noga SJ
    Exp Hematol; 1999 Jul; 27(7):1219-25. PubMed ID: 10390198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.
    Koh MB; Prentice HG; Lowdell MW
    Bone Marrow Transplant; 1999 May; 23(10):1071-9. PubMed ID: 10373075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multilineage engraftment with minimal graft-versus-host disease following in utero transplantation of S-59 psoralen/ultraviolet a light-treated, sensitized T cells and adult T cell-depleted bone marrow in fetal mice.
    Bhattacharyya S; Chawla A; Smith K; Zhou Y; Talib S; Wardwell B; Cowan MJ
    J Immunol; 2002 Dec; 169(11):6133-40. PubMed ID: 12444116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.